论文部分内容阅读
目的证实新制备的纯β射线免疫放疗制剂３５Ｓ－ＭｃＡｂＳＺ３９对胶质瘤的特异性杀伤作用。方法采用ＭＴＴ法，以人脑胶质瘤细胞系ＳＨＧ－４４为靶细胞，检测３５Ｓ－ＭｃＡｂＳＺ３９及其对照组３５Ｓ－ｎＩｇＧ；３５Ｓ＋ＭｃＡｂＳＺ３９；３５Ｓ持续作用组的细胞杀伤率，求取５０％细胞抑制浓度。结果３５Ｓ－ＭｃＡｂＳＺ３９的细胞杀伤力与３５Ｓ持续作用相近，较３５Ｓ－ｎＩｇＧ强４．２倍，较３５Ｓ＋ＭｃＡｂＳＺ３９强４．０倍（Ｐ＜０．０５）。结论３５Ｓ－ＭｃＡｂＳＺ３９具有高效的靶选择性细胞毒效应，作为一种免疫放疗制剂具有良好的应用前景。
Objective To confirm the specific killing effect of 35S-McAbSZ39, a newly prepared pure β-ray immunotherapy for glioma. Methods The cell killing rate of 35S-McAb SZ39 and its control group 35S-nIgG; 35S + McAbSZ39; 35S sustained-action group were determined by MTT method. The inhibitory concentration of 50% cytoskeleton was determined by using the human glioma cell line SHG- . Results The cytotoxicity of 35S-McAbSZ39 was similar to that of 35S, which was 4.2 times stronger than 35S-nIgG and 4.0 times stronger than that of 35S-McAbSZ39 (P <0.05). Conclusion 35S-McAbSZ39 has an efficient target-selective cytotoxic effect and has good application prospects as an immunoradiotherapy preparation.